Michael H. May  PhD
President & CEO Centre for Commercialization of Regenerative Medicine
CCRM: Regenerative Medicine Commercialization Through Global Collaboration

Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.
Michael May is currently President and Chief Executive Officer of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, federally incorporated, not-for-profit organization dedicated to supporting the development of foundational technologies that accelerate the commercialization of stem cell-and biomaterials-based technologies. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity.
Michael sits on a number of Boards and advisory committees including:  MaRS Innovation; the Ontario Institute of Regenerative Medicine (OIRM); the Centre for the Commercialization of Antibodies and Biologics (CCAB); the Department of Chemical Engineering and Applied Chemistry at the University of Toronto; the Industry Committee of the International Society for Stem Cell Research (ISSCR); the Executive Committee, Alliance for Regenerative Medicine (ARM); ExCellThera Ltd.; the Rick Hansen Institute Commercialization Program Advisory Committee; Toronto Region Board of Trade Life Sciences Steering Committee; the NSERC CREATE M3 Program Committee; and the Cell and Gene Therapy Insights, Editorial Advisory Board.